
Utkarsh Acharya DO FACP
Hematologic Oncology
Board certified hematologist-medical oncologist with expertise in cellular immunotherapy on faculty at The Ohio State University Wexner Medical Center / James Cancer Hospital. Prior faculty positions at Dana-Farber Cancer Institute / Harvard Medical School and Fred Hutch Cancer Center / University of Washington.
Join to View Full Profile
300 W 10th AveColumbus, OH 43210
Phone+1 614-293-5066
Fax+1 614-293-9449
Dr. Acharya is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
Clinical Expertise
- Hematology, Medical oncology, Adoptive immunotherapy, Hematologic oncology, Leukemia, Lymphoma, Multiple myeloma, Myelodysplasia, Myelofibrosis, T-cell adoptive tumor therapy, Acute myeloid leukemia
Education & Training
University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 2012 - 2015
Ohio State University HospitalResidency, Internal Medicine, 2010 - 2012
University of South Florida MorsaniInternship, Internal Medicine, 2009 - 2010
Ohio University Heritage College of Osteopathic Medicine in AthensClass of 2009
Wilmington CollegeB.S, Major: Biology/ Minor: Chemistry, 2004
Certifications & Licensure
MA State License 2018 - 2027
OH State License 2015 - 2027
WA State License 2016 - 2027
AZ State License 2012 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctor Castle Connolly, 2024-2025
- CMS Meaningful Use Stage 1 Certification Centricity Practice Solution, GE Healthcare, 2016
- Fellow American College of Physicians, 2015
Publications & Presentations
PubMed
- Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody.Anam Ashfaque, Yara Shatnawi, Shahzad Raza, Diana Basali, Jack Khouri
Blood Reviews. 2025-08-01 - 3 citationsTraining Hematologists/Oncologists for the Academic-Community Hybrid: Creating a Fellowship Framework for the Future.Daniel A Roberts, Jennifer Faig, Kelly Bodio-Downey, Jason Shpilsky, Kathleen Leahy
JCO Oncology Practice. 2023-06-01 - 63 citationsAllogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.Joanna Zurko, Jeremy Ramdial, Mazyar Shadman, Sairah Ahmed, Aniko Szabo
Haematologica. 2023-01-01
Journal Articles
- DVT prophylaxis in long term care facilities - perhaps less is more.Acharya U, Khan S, Journal of American Medical Directors Association;12(4):313
- Teretocarcinoma in a Young Man with Testicular Torsion.Acharya U, Stroble S, Pepe L, Miocinovic R, Journal of histotechnology
- It doesn’t matter which sex students are.Acharya, U, studentBMJ ;14:89
Books/Book Chapters
Abstracts/Posters
- Does Gastric Acid Suppressive Therapy Increase the Risk of Pneumonia in Older Adults?Gau J-T, Acharya U, Kao T, Khan S, Moy J, Carlsen W, Journal of American Geriatrics Society. Annual Meeting Abstract Supplement, Seattle, WA
- Effects of Eukarytoic Cell Cycle Inhibitors on Toxoplasma gondii.Acharya U, Woodmansee, D, Annual Biomedical Research Conference for Medical Students, San Diego, CA
- Effects of Ca2+/K+ flux on Trypanosoma cruzii Egress.Acharya U, Rowland E, Ohio University College of Osteopathic Medicine, Athens, OH
Other
- The Malignancies of Medicine.Acharya U, The Yale Journal for Humanities in Medicine.
http://yjhm.yale.edu/ - Am I going crazy?Acharya and U
http://www.mdconsult.com
Authored Content
- The COVID-19 Conundrum & Cancer - Making Perfect Sense of Imperfect DataMay 2020
Press Mentions
Dr. Utkarsh Acharya: On the Challenges, Pride and Frustrations of Treating CAR-T PatientsNovember 12th, 2018
Dr. Utkarsh Acharya: On “Why Become Involved in Immunotherapy and Cellular Therapies for Treating Cancer?”October 27th, 2018
Part 2: Why Seattle for My CAR-T Therapy to Demolish My CLL?April 5th, 2018
Professional Memberships
- Member
- Member
- Member
- Member
Other Languages
- Gujarati
Industry Relationships
- Medical Director, Bristol Myers SquibbMedical director in the cell therapy group of Bristol Myers Squibb.2022 - 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:












